BioTime, Inc. (NYSE: BTX) is building a dominant company in the field of regenerative medicine. The company’s strategy is to be the leader in the development of pluripotent stem cell-based technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide. BioTime has also advanced other products into human clinical trials during the past year. For more information, visit the company’s website at www.biotimeinc.com.